leisure time -WSS

leisure time

author：leisure time 2025-10-01 20:15:57 - browse：1

JOSEPH PREZIOSO/AFP via Getty Images

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Long Covid research funding gets a major boost from NIH

hotspot

WSS

Artificial intelligence use in health care faces greater scrutiny in 2024

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Feed a cold, starve a fever? Here’s what science says

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Restaurant meals are packed with calories, and we still keep eating them

entertainment

leisure time

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

Judge in Trump's classified documents case questions use of out

How one medical school became remarkably diverse

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Moonlake's readout produced a cash windfall. Risks remain

Google's generative AI to analyze medical images — and talk to docs

Jerome Adams on the need for new antivirals for Covid

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Anesthesiologist group: stop taking Ozempic before surgery

With heat waves through August, officials warn of health risks

explore

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Congress might make insulin pumps more accessible to the blind

With heat waves through August, officials warn of health risks

Doctors on social media are being harassed and cyberbullied

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

Many breast cancer patients receive more radiation than needed

focus

knowledge

hotspot

hotspot